Citation Impact
Citing Papers
Vaccine-delivered HIV envelope inhibits CD4+ T-cell activation, a mechanism for poor HIV vaccine responses
2006 StandoutNobel
Maturation-Dependent HIV-1 Surface Protein Redistribution Revealed by Fluorescence Nanoscopy
2012 StandoutScienceNobel
Memory CD8 + T Cells Are Required for Protection from Persistent Hepatitis C Virus Infection
2003 StandoutNobel
Bispecific antibodies for cancer therapy
2009
Current progress in development of hepatitis C virus vaccines
2013
Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge
2017 StandoutNobel
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
2013 Standout
Cell-Mediated Immune Proliferative Responses to HIV-1 of Chimpanzees Vaccinated with Different Vaccinia Recombinant Viruses
1989 StandoutNobel
The β-Chemokine Receptors CCR3 and CCR5 Facilitate Infection by Primary HIV-1 Isolates
1996 Standout
Identification of Two Neutralizing and 8 Non-Neutralizing Epitopes on Simian Immunodeficiency Virus Envelope Using Monoclonal Antibodies
1992
Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know
2004
Strictly Target Cell-dependent Activation of T Cells by Bispecific Single-chain Antibody Constructs of the BiTE Class
2007
Long-Term Observation of Baboons, Rhesus Monkeys, and Chimpanzees Inoculated with HIV and Given Periodic Immunosuppressive Treatment
1989
Passive Immunotherapy in the Treatment of Advanced Human Immunodeficiency Virus Infection
1993
Somatic insertions and deletions shape the human antibody repertoire 1 1Edited by J. Karn
1999 StandoutNobel
HIV-1 envelope-elicited neutralizing antibody titres correlate with protection and virus load in chimpanzees
1994
Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1
1997
Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody
1998 StandoutNature
HIV vaccines 1983–2003
2003
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Structure of Dengue Virus
2002 Standout
Requirement for multiple lymphocyte subsets in protection by a live attenuated vaccine against retroviral infection
1999
CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis
2006
HIV-1 antibody serum negativity with urine positivity
1993 StandoutNobel
Functional Impairment of CD8+ T Cells by Regulatory T Cells during Persistent Retroviral Infection
2004 StandoutNobel
Elimination of large tumors in mice by mRNA-encoded bispecific antibodies
2017 StandoutNobel
The fastest genome evolution ever described: HIV variation in situ
1993
Molecular Characterization of Variable Heavy and Light Chain Regions of Five HIV Type 1-Specific Human Monoclonal Antibodies*
1994
Diversity of V3 Region Sequences of Human Immunodeficiency Viruses Type 1 from the Central African Republic
1993 StandoutNobel
Development of HIV/AIDS Vaccine Using Chimeric gag-env Virus-Like Particles
1999
HIV Vaccines: New Frontiers in Vaccine Development
2006
Restoring function in exhausted CD8 T cells during chronic viral infection
2005 StandoutNatureNobel
HIV as the cause of AIDS
1996 StandoutNobel
The quest for an AIDS vaccine: is the CD8+ T-cell approach feasible?
2002
Increased surface expression of HIV-1 envelope is associated with improved antibody response in vaccinia prime/protein boost immunization
2017 StandoutNobel
Absence of Intact nef Sequences in a Long-Term Survivor with Nonprogressive HIV-1 Infection
1995
Modulation of EZH2 expression in T cells improves efficacy of anti–CTLA-4 therapy
2018 StandoutNobel
Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
1995 StandoutNature
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial
2008 Standout
Passively transferred antibodies directed against conserved regions of SIV envelope protect macaques from SIV infection
1993
Understanding the hepatitis C virus life cycle paves the way for highly effective therapies
2013 StandoutNobel
Heterologous Epitope-Scaffold Prime∶Boosting Immuno-Focuses B Cell Responses to the HIV-1 gp41 2F5 Neutralization Determinant
2011 StandoutNobel
Comparison of serum antibody reactivities to a conformational and to linear antigenic sites in the external envelope glycoprotein of simian immunodeficiency virus (SIVmac) induced by infection and vaccination
1993
Macrophage-tropic HIV and SIV envelope proteins induce a signal through the CCR5 chemokine receptor
1997 StandoutNatureNobel
HIV-1 Neutralization Profile and Plant-Based Recombinant Expression of Actinohivin, an Env Glycan-Specific Lectin Devoid of T-Cell Mitogenic Activity
2010 StandoutNobel
A Strategy for Prophylactic Vaccination Against HIV
1993 Science
Synthesis of Heterobifunctional Protein Fusions Using Copper‐Free Click Chemistry and the Aldehyde Tag
2012 StandoutNobel
Virus-like particles: Designing an effective AIDS vaccine
2006
Development of Virus-Like Particle Technology from Small Highly Symmetric to Large Complex Virus-Like Particle Structures
2013 Standout
Long-Term Control of HIV by CCR5 Delta32/Delta32 Stem-Cell Transplantation
2009 Standout
Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus.
1991 StandoutNobel
Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates
2011 StandoutNobel
HIV Population Dynamics in Vivo: Implications for Genetic Variation, Pathogenesis, and Therapy
1995 StandoutScience
TaqMan 5′-Nuclease Human Immunodeficiency Virus Type 1 PCR Assay with Phage-Packaged Competitive Internal Control for High-Throughput Blood Donor Screening
2001
Intensified and protective CD4+ T cell immunity in mice with anti–dendritic cell HIV gag fusion antibody vaccine
2006 StandoutNobel
Major histocompatibility complex class I-associated vaccine protection from simian immunodeficiency virus-infected peripheral blood cells.
1994
CD81 Is Required for Hepatitis C Virus Glycoprotein-Mediated Viral Infection
2004 StandoutNobel
Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1
1994
Identification of RANTES, MIP-1α, and MIP-1β as the Major HIV-Suppressive Factors Produced by CD8 + T Cells
1995 StandoutScience
Adaptation to persistent growth in the H9 cell line renders a primary isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccine sera
1995
Characterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120
1993
Control of Viremia in Simian Immunodeficiency Virus Infection by CD8 + Lymphocytes
1999 StandoutScience
T- and B-lymphocyte responses to human immunodeficiency virus (HIV) type 1 in macaques immunized with hybrid HIV/hepatitis B surface antigen particles
1990
Emergence of viruses resistant to neutralization by V3-specific antibodies in experimental human immunodeficiency virus type 1 IIIB infection of chimpanzees
1990
Effective Induction of Simian Immunodeficiency Virus-Specific Cytotoxic T Lymphocytes in Macaques by Using a Multiepitope Gene and DNA Prime-Modified Vaccinia Virus Ankara Boost Vaccination Regimen
1999
Differential glycosylation, virion incorporation, and sensitivity to neutralizing antibodies of human immunodeficiency virus type 1 envelope produced from infected primary T-lymphocyte and macrophage cultures
1996
Protection against lethal simian immunodeficiency virus SIVsmmPBj14 disease by a recombinant Semliki Forest virus gp160 vaccine and by a gp120 subunit vaccine
1996
Alphavirus-based expression vectors: strategies and applications.
1996 StandoutNobel
Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy
1997 Standout
Pathogenesis of human immunodeficiency virus infection
1993
Immunological and Virological Analyses of Persons Infected by Human Immunodeficiency Virus Type 1 while Participating in Trials of Recombinant gp120 Subunit Vaccines
1998
Viral dynamics in human immunodeficiency virus type 1 infection
1995 StandoutNature
High viral load in lymph nodes and latent human immunodeficiency virus (HIV) in peripheral blood cells of HIV-1-infected chimpanzees
1993 Nobel
In Vivo Targeting of Antigens to Maturing Dendritic Cells via the DEC-205 Receptor Improves T Cell Vaccination
2004 StandoutNobel
Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome
1994 Standout
Vaccine-induced neutralizing antibodies directed in part to the simian immunodeficiency virus (SIV) V2 domain were unable to protect rhesus monkeys from SIV experimental challenge
1994
HIV Gag mRNA Transfection of Dendritic Cells (DC) Delivers Encoded Antigen to MHC Class I and II Molecules, Causes DC Maturation, and Induces a Potent Human In Vitro Primary Immune Response
2000 StandoutNobel
Genetic Restriction of HIV-1 Infection and Progression to AIDS by a Deletion Allele of the CKR5 Structural Gene
1996 StandoutScience
Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1
1995 StandoutNobel
Hepatitis C Virus Glycoproteins Interact with DC-SIGN and DC-SIGNR
2003 StandoutNobel
The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens
1998 StandoutScience
Protection of Macaques against Pathogenic Simian/Human Immunodeficiency Virus 89.6PD by Passive Transfer of Neutralizing Antibodies
1999
Passive immunotherapy for retroviral disease: influence of major histocompatibility complex type and T-cell responsiveness.
1995
Design of a hyperstable 60-subunit protein icosahedron
2016 StandoutNatureNobel
Human immunodeficiency virus type 1 challenge of chimpanzees immunized with recombinant envelope glycoprotein gp120.
1988
Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody
2008 Science
Structural basis for Zika envelope domain III recognition by a germline version of a recurrent neutralizing antibody
2020 StandoutNobel
Immunological Memory and Protective Immunity: Understanding Their Relation
1996 StandoutScience
Antigen targeting to dendritic cells elicits long-lived T cell help for antibody responses
2006 StandoutNobel
Passive immunotherapy in AIDS: a double-blind randomized study based on transfusions of plasma rich in anti-human immunodeficiency virus 1 antibodies vs. transfusions of seronegative plasma.
1995 StandoutNobel
Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic.
1992 Standout
Progress toward active or passive HIV-1 vaccination
2016
The microbial mimic poly IC induces durable and protective CD4+T cell immunity together with a dendritic cell targeted vaccine
2008 StandoutNobel
Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding
1993
Works of KATHY E. COBB being referenced
Redefining the HIV‐infectious window period in the chimpanzee model: evidence to suggest that viral nucleic acid testing can prevent blood‐borne transmission
1999
Prevention of HIV-1 infection in chimpanzees by gpl20 V3 domain-specific monoclonal antibody
1992 Nature
T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct
2005
Prevention of HIV Infection by Passive Immunization with HIV Immunoglobulin
1991
T-cell responses to human immunodeficiency virus (HIV) and its recombinant antigens in HIV-infected chimpanzees
1987
Transmission of Simian Immunodeficiency Virus SIVcpz and the Evolution of Infection in the Presence and Absence of Concurrent Human Immunodeficiency Virus Type 1 Infection in Chimpanzees
2006